Adicet Bio to Present at Upcoming Investor Conferences
07 Settembre 2022 - 10:10PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first-in-class allogeneic gamma
delta chimeric antigen receptor (CAR) T cell therapies for cancer,
today announced that company management will participate in two
upcoming investor conferences in September.
Details of the events are as follows:
H.C. Wainwright 24th Annual Global Investment Conference,
September 12-14, 2022, New York, New York
- An on-demand presentation given by Chen Schor, President &
CEO will be available beginning Monday, September 12, 2022 at 7:00
A.M. ET
Jefferies Cell and Genetic Medicine Summit, September 29-30,
2022, New York, New York
- Chen Schor, President & CEO, will present a corporate
overview on Friday, September 30, 2022, at 8:00 A.M. ET.
The live audio webcast of the presentations can be accessed on
the Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors and T
cell receptor-like targeting moieties to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website at
http://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220907006190/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024